Hikma Pharmaceuticals Commits $1 Billion to Expand US Generic Medicine Manufacturing Through 2030
Key Insights
Hikma Pharmaceuticals USA announces a $1 billion investment by 2030 to expand its US manufacturing and R&D capabilities for generic medicines (search).
The investment builds on the company's existing capacity to produce more than 12 billion finished doses annually across facilities in Ohio and New Jersey.
The expansion will strengthen Hikma's portfolio of over 800 medicines and enhance its position as a top three US supplier of sterile injectable medicines (search).
Hikma Pharmaceuticals USA announced a major $1 billion investment commitment through 2030 to significantly expand its domestic manufacturing and research capabilities for generic medicines (search). The investment, unveiled at a groundbreaking event in Columbus, Ohio, represents the company's latest phase in strengthening America's pharmaceutical supply chain independence.
Expanding Domestic Manufacturing Capacity
The investment initiative, branded "America Leans on Hikma: Quality Medicines Manufactured in the USA," will enhance production capabilities across Hikma's existing R&D and manufacturing sites in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey. The expansion builds on Hikma's established infrastructure, which currently has annual domestic capacity to produce more than 12 billion finished doses of essential medicines.
Hikma has operated in the US since 1991 and has invested more than $4 billion over the past 15 years to build and expand its US-based capabilities. The company maintains a portfolio of more than 800 medicines and employs 2,300 people across its US operations.
Leadership in Injectable Medicine Supply
Dr. Bill Larkins, President of Hikma Injectables, highlighted the company's significant market position: "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines (search) by volume with more than 180 injectable products in our portfolio and a growing pipeline." The new investment phase will specifically enhance and expand sterile injectables production capabilities.
The company has established an excellent record with US FDA quality inspections and has successfully collaborated with the FDA to address critical drug shortages, demonstrating its role in maintaining pharmaceutical supply chain stability.
Strategic Impact on Healthcare Access
Dr. Hafrun Fridriksdottir, President of Hikma Rx, emphasized the patient-focused mission: "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines."
The investment addresses America's growing need for high-quality, domestically manufactured medicines while providing patients access to generic alternatives at lower costs than branded products. This expansion is expected to increase the company's capacity to produce large volumes of affordable medicines for American hospitals, healthcare providers, and patients.
Political and Economic Support
The announcement received support from elected officials, including US Representatives Mike Carey (OH-15) and Buddy Carter (GA-01), who attended the groundbreaking event. Rep. Carter, who serves as Chairman of the American-Made Medicines Caucus, stated: "It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America."
Rep. Carey emphasized the economic benefits for Ohio: "This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines."
The investment represents a significant commitment to domestic pharmaceutical manufacturing at a time when supply chain resilience has become a critical healthcare policy priority.